PER-107-08已完成未知
The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma
EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),0 个研究点目标入组 0 人开始时间: 2009年8月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 0（—）
- 性别
- Female
入选标准
- •Patients will be required to have the clear cell variant of renal cell carcinoma with less than 25% of any other histology (including, but not limited to, papillary or chromophobe or oncocytic); there must be histologic confirmation by treating center of either primary or metastatic lesion
- •Patients will be required to have measurable metastatic disease that is not curable by standard radiation therapy or surgery; all sites must be assessed within 4 weeks prior to study entry
- •Previous nephrectomy is required with the following exceptions: Primary tumor =< 5 cm, or Extensive liver (> 30% of liver parenchymal) or multiple (> 5) bone metastases, making nephrectomy a clinically questionable procedure, Unresectable primary tumor due to invasion into adjacent organs or encasing the aorta or vena cava
- •Prior radiation therapy is permitted, but toxicities from radiation must have resolved and a minimum of 2 weeks must pass prior to randomization
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Life expectancy of greater than 12 weeks
- •Hemoglobin (Hgb) >= 9.0 g/dL (transfusions allowed prior to enrollment)
- •White blood count (WBC) >= 3,000/mm^3
- •Absolute granulocyte count (AGC) >= 1,200/mm^3
- •Platelet count >= 100,000/mm^3
- •Serum creatinine =< 1.5 x upper limit of normal (ULN) or serum creatinine clearance (CrCl) >= 55 ml/min
- •Total bilirubin =< 1.5 x ULN
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (or =< 5.0 x ULN in the presence of liver metastases)
- •International normalized ratio (INR) =< 1.5
- •Activated partial thromboplastin time (aPTT) within normal limits
- •Fasting cholesterol < 350 mg/dL (9.0 mmol/L)
- •Fasting triglycerides < 400 mg/dL (4.56 mmol/L)
- •Patients must not have other current malignancies, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, and ductal or lobular carcinoma in situ of the breast; patients with other malignancies are eligible if they have been continuously disease-free for >= 5 years prior to the time of randomization
- •Any condition that impairs patient´s ability to swallow pills will make patient ineligible
- •Patients currently taking any of the following cytochrome P450 enzyme-inducing drugs are ineligible: Phenytoin, Carbamazepine, Phenobarbital, Rifampin
- •Pregnant and breastfeeding women are excluded from the study; breastfeeding should be discontinued while receiving therapy; patients must have pregnancy test within 7 days prior to patient randomization if woman is of child-bearing capacity
- •Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
排除标准
- •prior cytotoxic chemotherapy; a maximum of one prior regimen of either vaccine or cytokine-based immunotherapy disease is permitted
- •prior anti-angiogenic therapy including, but not limited to, SU11248, ZD6474 or VEGF Trap; no prior therapy with bevacizumab, mammalian target of rapamycin (mTOR) inhibitors (including, but not limited to, temsirolimus), or sorafenib will be allowed; thalidomide or interferon alpha (IFNalpha) are allowed either for adjuvant therapy or stage IV disease
- •immunotherapy within 4 weeks of randomization; toxicities from immunotherapy must have resolved and a minimum of two weeks must pass prior to enrollment
- •history or clinical evidence of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastasis, or history of stroke within the past 48 weeks
- •history of allergic reactions attributed to Chinese hamster ovary cell products, other recombinant human antibodies, or compounds of similar chemical or biologic composition to sorafenib, temsirolimus or bevacizumab
- •history of bleeding diathesis or coagulopathy
- •uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring parenteral antibiotics on day 0 or psychiatric illness/social situations that would limit compliance with study requirements
- •serious, non-healing wound, ulcer, or bone fracture
- •significant proteinuria at baseline; urine protein must be screened within 2 weeks prior to randomization by urine analysis for urine protein creatinine (UPC) ratio; if UPC ratio is > 0.5, 24-hour urine protein is to be obtained and the level must be < 1000 mg for patient enrollment
- •major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to randomization
- •anticipated need for major surgery during the course of the study
- •current or recent (within 4 weeks of enrollment) use of full-dose of anticoagulants or thrombolytic agents (except as required to maintain patency of preexisting or permanent indwelling IV catheters, for those patients receiving warfarin, INR must be =< 1.5)
- •clinically significant cardiovascular disease
研究者
相似试验
已完成
3 期
Tecentriq_SCLC(1L)_Bev_comb[BEAT-SC]Extensive-stage Small Cell Lung CancerJPRN-jRCT2080224946Chugai Pharmaceutical Co., Ltd.330
进行中（未招募）
1 期
A study evaluating efficacy of the drug BGB-290 in patients with gastric cancer that responded to previous chemotherapyInoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line ChemotherapyMedDRA version: 21.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003493-13-GBBeiGene, Ltd.128
已完成
2 期
BGB-290-303Inoperable Locally Advanced or Metastatic GastricCancerJPRN-jRCT2080225173Beigene ( ICCC: Parexel International)11
进行中（未招募）
1 期
A study evaluating efficacy of the drug BGB-290 in patients with gastric cancer that responded to previous chemotherapyEUCTR2017-003493-13-PLBeiGene Ltd.128
进行中（未招募）
1 期
A study evaluating efficacy of the drug BGB-290 in patients with gastric cancer that responded to previous chemotherapyInoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line ChemotherapyMedDRA version: 21.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003493-13-CZBeiGene, Ltd.540